Background Atezolizumab-bevacizumab (atezo-bev) is recommended as first-line therapy
for patients with unresectable hepatocellular carcinoma (uHCC). However, its effectiveness …

Hepatocellular carcinoma (HCC) has emerged the culprit of cancer-related mortality
worldwide with its dismal prognosis climbing. In recent years, ground-breaking progress has …

Abstract Background/Aim Atezolizumab plus bevacizumab (Atez/Bev) treatment is
recommended for unresechepatocellular carcinoma (u‐HCC) patients classified as Child …

Objective We conducted the first meta-analysis to identify the predictive significance of
baseline blood biomarkers (such as neutrophil to lymphocyte ratio (NLR), early alpha …

Summary Background and Aims Phase III trials have established atezolizumab plus
bevacizumab as the novel standard of care for patients with unresectable hepatocellular …

Aim We investigated pretreatment neutrophil‐to‐lymphocyte ratio (NLR) for predicting
survival outcomes of atezolizumab plus bevacizumab therapy for hepatocellular carcinoma …

A combination of atezolizumab with bevacizumab (AB) is the first regimen that has shown
superiority compared to sorafenib and is now being used as the systemic treatment of choice …

Background Atezolizumab plus bevacizumab was approved in 2020 as a first-line treatment
for advanced hepatocellular carcinoma (HCC). The purpose of this study was to assess the …

Simple Summary Atezolizumab plus bevacizumab therapy has high response rates in
patients with unresectable hepatocellular carcinoma (HCC). The hepatobiliary phase of …

Aim This study compared the efficacy and safety of atezolizumab and bevacizumab
(Atez/Bev) in patients with viral and non‐viral infection in clinical settings. Methods We …